Purpose: To report long-term (> 5 y) outcomes of plateau iris syndrome patients treated with argon laser peripheral iridoplasty (ALPI).
P rimary angle closure glaucoma (PACG) is a leading cause of blindness. It is estimated that 5.3 million people will be blind worldwide from PACG by 2020, 1 and the estimated number of those affected by PACG will rise from 23 million in 2020 to 32 million in 2040 worldwide. 2 Pupillary block, in which iris-lens apposition prevents the normal flow of aqueous, is the most common cause of primary angle closure (PAC). 3, 4 However, angle closure may also be caused by plateau iris syndrome (PIS), in which a larger than normal or anteriorly positioned ciliary body narrows the angle by physically apposing the iris root against the trabecular meshwork, inhibiting the flow of aqueous. 5 Laser peripheral iridotomy has long been considered the initial treatment for PAC by creating a conduit for aqueous flow that bypasses the pupillary block. Some eyes with gonioscopic plateau iris configuration are adequately treated with iridotomy alone. However, if a patent iridotomy fails to deepen the angle and lower intraocular pressure (IOP), PIS is the likely etiology. 5, 6 Patients with PIS are treated with argon laser peripheral iridoplasty (ALPI), where multiple laser burns are placed in the peripheral iris to deepen the angle recess by contracting the iris and pulling it away from the trabecular meshwork. When ALPI and/or medications fail to adequately control IOP, filtering surgery or phacoemulsification lens extraction may be necessary.
Ritch et al 6 reported that in their study 20 of 23 PIS eyes (87%) remained open 6.5 years after a single treatment of ALPI. Despite the high percentage of angles that deepened after a single ALPI treatment, the changes of IOP were not statistically different from pre-ALPI to the last visit. In addition, IOP remained elevated (IOP > 21 mm Hg) in 5 of 23 eyes (22%), and 10 eyes (43%) were on pilocarpine at the last follow-up. Although only 1 eye underwent phacoemulsification during the follow-up period, the mean visual acuity was significantly decreased due to cataract development. Thus, the overall clinical efficacy of ALPI for treating PIS may have to be reevaluated.
The goal of this study is to report long-term overall clinical outcomes of ALPI for patients with PIS, with success defined as IOPr21 mm Hg without the need for IOPlowering drops, filtering surgery, or phacoemulsification.
PATIENTS AND METHODS
A retrospective chart review was performed to identify all patients with PIS who were treated with ALPI at the Robert Cizik Eye Clinic of the Ruiz Department of Ophthalmology and Visual Science at the McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth) from 1996 to 2007 and followed for at least 1 year. This study was reviewed and approved by The University of Texas Committee for the Protection of Human Subjects (Institutional Review Board/Ethics Committee). All research followed the tenets of the Declaration of Helsinki and was Health Insurance Portability and Accountability Act compliant.
Study Population
Charts were identified using Current Procedural Terminology codes corresponding to ALPI, and only patients with a diagnosis of nonacute PAC who had a patent peripheral iridotomy at the time of ALPI were included. Patients were excluded if they had any previous intraocular surgery or <1 year of follow-up. In each patient, only the first eligible eye treated with ALPI was selected.
A clinical diagnosis of PIS was based on the criteria suggested by Tran et al 7 that despite the presence of a patent peripheral iridotomy during dark room gonioscopic examination, the presence of iridotrabecular appositional angle close, an iris root angulating forward and then centrally, a flat or slightly convex iris contour, and a double hump sign on indentation gonioscopy is required.
Gonioscopic Examination
Gonioscopy was performed using a Posner 4-mirror lens at high magnification (10 Â), with the eye in the primary position of gaze under the lowest possible ambient lighting conditions by turning off all ambient light sources and closing the door of the examination room. Gonioscopic examination was first performed without indentation, with care taken to minimize light from the slit lamp beam from entering the pupil.
Gonioscopic examination results were recorded before and after the ALPI procedure and routinely at subsequent visits to monitor for any angle configuration changes. Peripheral angles were graded using the Spaeth grading system, 8, 9 and iris bow and presence or absence of peripheral anterior synechiae (PAS) were recorded.
ALPI Procedures
ALPI was performed by 1 of 2 glaucoma specialists (R.M.F. or N.P.B.). Each surgeon used similar techniques. Typical ALPI settings were a spot size of 200 to 400 mm with a power of 250 to 500 mW per shot for 0.2 seconds, titrated until a visible contraction of the iris was noted. No lens was used during the procedure.
Data Collection
Data collected included participant demographics, visual acuity, IOP, number of IOP-lowering medications, gonioscopic examination, glaucomatous visual field and/or optic disc damage, and the dates, types, and reason of subsequent procedures (ie, repeat ALPI, phacoemulsification, or trabeculectomy). Scheduled study visits included the pre-ALPI (baseline) visit and all appointments post-ALPI corresponding to annual ( ± 6 mo) visits. If no data were recorded in a scheduled follow-up window, this was considered as missing data at that timepoint. If an eye underwent trabeculectomy after ALPI, the last visit was the visit before trabeculectomy.
Data Analysis
Demographic and baseline clinical data were summarized by mean ( ± SD) or frequency (percentage) for categorical variables. Snellen best-corrected visual acuity (BCVA) was converted to logMAR by -log 10 (BCVA). The paired t test was used to compare changes of IOP, number of IOP-lowering medications, and BCVA from baseline to annual follow-up.
The primary outcome measure was the incidence for needing any IOP-lowering medical or surgical treatment. A complete success was defined as IOPr21 mm Hg without IOP-lowering medications, filtration surgery, and/or phacoemulsification. A qualified success was defined as an eye without additional filtration surgery and/or phacoemulsification. A repeat ALPI during the follow-up period was not considered as an additional surgical treatment or failure of the initial ALPI procedure. The secondary outcome was to compare the extent of angle opening grades at the first and the last visit after ALPI to before ALPI.
All statistical tests were conducted at a 5% level of significance. Analysis was performed using SAS software version 9.4 for Windows (SAS Institute Inc., Cary, NC).
RESULTS
In total, 30 patients with 49 eyes that underwent ALPI between February 1996 and June 2007 were identified. A total of 27 eyes were excluded from the study for the following reasons: 5 eyes from 3 patients did not have a previous iridotomy; 5 eyes from 4 patients had an iridotomy performed after ALPI; 4 eyes from 3 patients had <12 months of follow-up; and 13 eyes were the second eye of previously included patients. Thus, we included a total of 22 eyes from 22 participants in our study (Fig. 1 ). The mean age was 57.7 ( ± 10.2) years. Four (18%) participants were male. Fourteen (64%) participants were white, 5 (23%) Hispanic, and 3 (14%) black. Fourteen (64%) study eyes were the right eyes. Eyes were followed for a mean of 76 months ( ± 39), ranging from 19 to 170 months.
Baseline Characteristics
Gonioscopy before the procedure revealed appositional closure with Spaeth grade A or B in 4 (18%) and 12 (53%) eyes, respectively. Six (29%) eyes with Spaeth grade C had a plateau iris configuration as determined by gonioscopy (steep insertion and a double hump sign by indentation gonioscopy) and verified by ultrasound biomicroscopy. In addition, 4 of these 6 eyes had elevated IOP. Eighteen (82%) eyes had no iris bow, and 7 (32%) eyes had PAS.
Eleven eyes (50%) had elevated IOP (> 21 mm Hg or on IOP-lowering medications) at baseline. Seven (32%) eyes used at least 1 IOP-lowering medication, and 2 (9%) eyes had glaucomatous visual field damage with or without optic nerve damage. The mean ( ± SD) treated IOP and logMAR visual acuity were 21.3 ( ± 7.1) mm Hg and 0.32 ( ± 0.84) logMAR, respectively. ALPI was performed at a mean time of 33.7 months ( ± 71.7) after initial iridotomy (Table 1) .
Outcomes

Gonioscopy
A gonioscopic examination was performed in 21 of 22 study eyes (95%) during the first follow-up visit after ALPI. Spaeth grading showed that the angle deepened in 15 eyes (71%) by at least 1 grade (Table 2 ) and did not improve in 6 eyes (29%) after ALPI. Of these 6 eyes with no improvement in angle grading, 3 eyes had peripheral iris flattening from steep to regular and/or angular approaches increased by at least 10 degrees. In the other 3 eyes, the angle did not deepen after the first ALPI treatment, and repeat ALPI was performed.
Ten of 21 (48%) gonioscopically examined eyes were open to at least Spaeth grade C at the last follow-up visit or before additional surgery (phacoemulsification or trabeculectomy).
Repeat ALPI
Seven eyes were either not improved after the initial treatment (3 eyes) and/or gradually narrowed during the follow-up period and required a repeat ALPI at an average of 48 months ( ± 30) after the initial ALPI. All angles were deepened by at least 1 Spaeth grade after repeat ALPI, except 1 eye where appositional closure was not deepened, but the peripheral iris grade was no longer steep (Table 3) .
IOP and Number of IOP-lowering Medications
The mean IOP measured at the first visit after initial ALPI was 16.6 mm Hg ( ± 5.9), which was reduced by 4.7 mm Hg ( ± 6.7) from baseline IOP (P = 0.004). Of 7 eyes on IOP-lowering medications before ALPI, 1 eye was not using medications at the first postoperative visit, and medications were increased in 2 eyes. No medications were added to the eyes which were not on IOP-lowering medications preoperatively (Table 4) .
At the last visit or the visit before additional treatment, the mean IOP [19.7 mm Hg ( ± 6.4)] gradually increased to the baseline level [21.3 mm Hg ( ± 7.1), P = 0.38], but the number of the eyes on IOP-lowering medications doubled from 7 eyes at baseline to 14 (64%) eyes.
Additional Treatment
Two eyes (9%) eyes did not require any medication or surgery (complete success), and 3 eyes required IOPlowering medications without any other IOP-lowering procedures (qualified success). The remaining 17 eyes (77%) required a surgical procedure at a mean time of 49.1 months ( ± 7.9) after the initial ALPI (Fig. 2) . Eight (36%) eyes required filtering surgery with or without phacoemulsification with intraocular lens implantation, and 9 (41%) eyes underwent phacoemulsification with intraocular lens implantation alone (Fig. 2) . The indication for additional medical and surgical treatment for each participant is listed in Table 4 with Spaeth grade, IOP, and number of IOP-lowering medications at visits before ALPI, first visit after ALPI, and before additional treatment.
Eight eyes underwent filtering surgery with or without phacoemulsification and intraocular lens implantation after ALPI. The indications for surgery were progressive glaucomatous visual field and/or optic disc damage (n = 3) and uncontrolled IOP on maximum tolerated IOP-lowering medications (n = 3). The remaining 2 eyes underwent unplanned trabeculectomy with anterior vitrectomy due to vitreous prolapse in a planned surgical iridectomy. All 6 eyes that underwent planned trabeculectomy were on IOPlowering medications with a mean treated IOP of 23.3 mm Hg ( ± 8.2) before additional surgery.
Nine eyes underwent phacoemulsification and intraocular lens implantation only. Four eyes had cataracts with visual acuities worse than 20/40 and a stable angle before the cataract surgery. Three eyes had visual acuities of 20/20 and underwent a clear lens extraction for the purpose of deepening the angle. Two eyes had cataracts with angle narrowing. These 9 eyes were followed for a mean of 41 months ( ± 42) after phacoemulsification and intraocular lens implantation. The 5 eyes that had angle narrowing before phacoemulsification were deepened by 1 to 3 Spaeth grades, and all 9 eyes had angles opened to Spaeth grades C or D. In addition, 5 of 9 eyes that were using IOP-lowering medications before surgery were free of IOP-lowering medications with IOP < 21 mm Hg. All eyes had visual acuity 20/30 or better at the last visit (Table 5) .
Annual IOP and Visual Acuity Table 6 shows the treated IOP, number of IOPlowering medications, and visual acuity at the annual follow-up visits for eyes before additional surgical treatment. Treated IOP was significantly reduced at year 1 and then gradually increased by year 5. After year 2, the number of IOP-lowering medications used significantly increased. Visual acuity after ALPI decreased between years 2 and 4.
DISCUSSION
ALPI involves the application of argon laser to the peripheral iris, resulting in immediate shrinkage due to coagulation of collagen, followed by the long-term formation of fibroblastic membranes that contract the iris, ultimately pulling it away from the angle. 10 Although ALPI is sometimes used to help break acute attacks of PAC, 3 it is often utilized to treat PIS after iridotomy fails to deepen the angle. In addition, ALPI may reduce the need for filtration surgery in PACG eyes with patent iridotomy. 11 In this study, we demonstrated that while ALPI is effective in the short term, the majority of eyes required surgical intervention to manage progressive angle narrowing and control IOP. In addition, our findings suggest that phacoemulsification alone may be a successful treatment for patients with PIS.
Our results showed that at year 1 the majority of patients that underwent ALPI had their IOP controlled on topical medication. However, in our study, at 2 years after ALPI, additional IOP-lowering medications became increasingly necessary, suggesting that the effects of ALPI were subsiding. Visual acuity also decreased over this time period. Given the age of our participant population, this is likely attributed to cataract formation, and less likely to be a direct result of ALPI.
Most prior studies examining success rates of ALPI in PAC eyes either evaluated the acute angle closure attack setting or had only short-term follow-up. However, one other long-term study by Ritch and colleagues followed 23 eyes from 14 patients with PIS treated with ALPI after iridotomy for an average of 6.5 years and reported that 3 eyes (13%) had gradual reclosure of the angle that required a repeat ALPI procedure to reopen the angle; 1 eye (4%) developed progressive glaucomatous visual field damage; and 3 eyes (13%) required further glaucoma procedures (2 eyes required argon laser trabeculoplasty and 1 eye required a repeat iridotomy for closure of iridotomy). 6 In our study, although ALPI did help open angles with PIS, the effects were short-lived. Seventeen patients (77%) required filtering surgery and/or phacoemulsification after 4 years.
The differences between our findings and those in the Ritch and colleagues study are likely attributed to different patient populations, ALPI settings, outcome measures, and different management options available to the treating physicians. First, our study eyes had higher IOP (mean IOP = 21.3 mm Hg) before ALPI with less eyes on IOPlowering medications [7 eyes (33%) on 1 to 2 medications] compared with Ritch et al 6 study [mean IOP = 18 mm Hg with 16 eyes (70%) on pilocarpine, 7 (30%) on beta blockers, 2 (9%) on dipivefrin, and 2 (9%) on oral acetazolamide]. In addition, 7 eyes (33%) in our study had PAS, and 2 eyes (9%) had glaucomatous damage before ALPI, whereas PAS was not documented and no eyes had glaucomatous damage in the Ritch et al study. 6 It is likely that our study population had more advanced disease than the patients in the Ritch and colleagues study.
Second, to avoid atrophic iris scarring, our ALPI settings were of less strength (spot size of 200 to 400 mm for 0.2 s) and required more applications (mean 36 spots) compared with the settings in Ritch et al 6 (spot size of 500 mm for 0.5 s with an average of 29 spots). It is expected that a repeat ALPI may be required using our settings; thus, an eye with repeat ALPI was not considered as a failure of ALPI treatment. Third, the long-term outcome after ALPI was assessed using the criteria proposed by Rosman and colleagues for evaluating the outcome after laser peripheral iridotomy in chronic angle closure glaucoma eyes. The failure criteria were a rise in IOP (IOP > 21 mm Hg) during follow-up and requiring treatment by medication or surgery (as deemed necessary by the clinician involved). 11 These outcome measures were created to treat the patient and not just the angle.
Finally, the management options were different between the 2 studies. Visual acuity at the last visit was significantly reduced from pre-ALPI in the Ritch and colleagues study. Only 1 eye underwent phacoemulsification in their study; however, 11 eyes (48%) had a visual acuity of 20/40 or worse. 6 In our study, 9 patients (40%) who underwent phacoemulsification alone had the angle opened to Spaeth grade C or D and visual acuity of 20/30 or better at the last visit. All of these eyes were free of IOP-lowering medications with IOP < 21 mm Hg after phacoemulsification. A number of recent studies have demonstrated that lens extraction effectively lowers IOP and maintains an open angle in eyes with PAC after laser peripheral iridotomy. [12] [13] [14] It is not clear exactly why the IOP drops after cataract surgery. Several possible hypotheses have been proposed: (1) slimmer intraocular lens replacement of the thicker crystalline lens deepens the anterior chamber and widens the angle 15, 16 ; (2) as the scleral spur relaxes after cataract surgery, the trabecular beams may be mechanically pulled open with consequent improved aqueous outflow 17 ; (3) trabecular endothelial remodeling due to ultrasonic energy from the phacoemulsification handpiece 18 or mechanical stretching caused by high intraoperative IOP 19 ; and (4) irrigation of the anterior chamber at the end of cataract surgery may flush debris in the angle. However, these are not definitive answers. A prospective randomized study comparing ALPI versus lens extraction as treatment (after iridotomy) could help determine the best clinical management for PIS.
Another difference in managing PIS patients between the 2 studies was that while no eyes underwent filtration surgery in the Ritch et al 6 study, 5 eyes had an elevated IOP (IOP > 21 mm Hg), 10 eyes were on pilocarpine, and 1 eye had visual field damage without additional incisional surgery. In our clinical practice, medical treatment was given to patients whose IOP > 21 mm Hg. If patients were intolerant to medications or noncompliant, trabeculectomy was performed to control disease progression. This may also contribute to the higher rate of filtration surgery in our study than in the Ritch and colleagues study.
There are limitations to our retrospective study. The extent of PAS was not documented consistently in the charts, and therefore a detailed, quantified extent of PAS was not available for all participants. Also, the decision to perform surgery and the type of procedure selected were based on the clinical discretion of the treating physician and not determined by strictly defined criteria. Consequently, our outcomes may be skewed by inherent management patterns and biases. In addition, our sample size was small, and it is uncertain if our findings may be extrapolated to the population at large. In summary, our study demonstrates a low long-term success rate of ALPI in controlling IOP in patients with PIS. After 4 years, the majority of participants required filtering surgery or phacoemulsification. Participants who underwent phacoemulsification were able to maintain an IOP < 21 mm Hg without IOP-lowering medications. Thus, phacoemulsification alone may be an effective treatment for patients with PIS. 
